John Gordon

Dr. John Gordon

orcid

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 1990 in Nature
Verified
Journal Article
Closed access
JGJohn Gordon
John Gordon
SGStephen J. Galli
Stephen J. Galli

1 January 1990 in Immunology Today
Verified
Journal Article
Closed access
JGJohn Gordon
John Gordon
PBParris R Burd
Parris R Burd
SGStephen J Galli
Stephen J Galli

1 July 1989 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PBP R Burd
P R Burd
HRH W Rogers
H W Rogers
JGJohn Gordon
John Gordon
CMC A Martin
C A Martin
SJS Jayaraman
S Jayaraman
MDM E Dorf
M E Dorf
In response to IgE and specific multivalent antigen, mast cell lines (both growth factor-dependent and -independent) induce the transcription and/or secretion of a number of cytokines having a wide spectrum of activities. We have identified IL-1, IL-3, IL-5, IL-6, IFN-gamma, GM-CSF, JE, MIP1 alpha, MIP1 beta, and TCA3 RNA in at least two of four mast cell clones. The production of these products (except JE) is activation-associated and can be induced by IgE plus antigen. In selected instances cytokine expression can also be induced by activation with Con A or phorbol ester plus ionophore, albeit to levels less than those observed with IgE plus antigen. In addition, long-term mast cell clones and primary cultures of bone marrow-derived mast cells specifically release IL-1, IL-4, and/or IL-6 bioactivity after activation. These findings suggest that in addition to their inflammatory effector function mast cells may serve as a source of growth and regulatory factors. The relationship of mast cells to cells of the T lymphocyte lineage is discussed.

1 December 1991 in Current Opinion in Immunology
Verified
Journal Article
Closed access
SGStephen J. Galli
Stephen J. Galli
JGJohn Gordon
John Gordon
BWBarry K. Wershil
Barry K. Wershil

29 June 2009 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
RSRoseMarie Stillie
RoseMarie Stillie
SFShukkur Muhammed Farooq
Shukkur Muhammed Farooq
JGJohn Gordon
John Gordon
ASAndrew W. Stadnyk
Andrew W. Stadnyk
The presence of two CXCL8 receptor types combined with the inflammatory roles of PMN has led to interest in whether each receptor type contributes to unique functions.PMN are critical to innate immunity and are fundamental to antibacterial defense. To localize to sites of infection, PMN possess receptors that detect chemoattractant stimuli elicited at the site, such as chemokines, complement split products, or bioactive lipids. Signaling through these receptors stimulates chemotaxis toward the site of infection but also activates a number of biochemical processes, with the result that PMN kill invading bacteria. PMN possess two receptors, CXCR1 and CXCR2, for the N–terminal ELR motif–containing CXC chemokines, although only two chemokine members bind both receptors and the remainder binding only CXCR2. This peculiar pattern in receptor specificity has drawn considerable interest and investigation into whether signaling through each receptor might impart unique properties on the PMN. Indeed, at first glance, CXCR1 and CXCR2 appear to be functionally redundant; however, there are differences. Considering these proinflammatory activities of activating PMN through chemokine receptors, there has been great interest in the possibility that blocking CXCR1 and CXCR2 on PMN will provide a therapeutic benefit. The literature examining CXCR1 and CXCR2 in PMN function during human and modeled diseases will be reviewed, asking whether the functional differences can be perceived based on alterations in the role PMN play in these processes.

1 January 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JGJohn Gordon
John Gordon
YMYanna Ma
Yanna Ma
LCLaura Churchman
Laura Churchman
SGSara A. Gordon
Sara A. Gordon
WDWojciech Dawicki
Wojciech Dawicki
We recognize well the abilities of dendritic cells to activate effector T cell responses to an array of antigens and we think of these cells in this context as pre-eminent antigen presenting cells, but dendritic cells are also critical to the induction of immunologic tolerance. Herein we review our knowledge around the different kinds of tolerogenic or regulatory dendritic cells that are present or can be induced in experimental settings and humans, how they operate and the disease in which they are effective, from allergic to autoimmune diseases and transplant tolerance. Central messages that arise from these cumulative studies clearly indicate that the agent(s) used to induce the tolerogenic phenotype and the status of the dendritic cell at the time of induction influence not only the phenotype of the dendritic cell, but also that of the regulatory T cell responses that they in turn mobilize. For example, while many, if not most, types of induced regulatory dendritic cells lead CD4+ naïve or effector T cells to adopt a CD25+Foxp3+ Treg phenotype, exposure of Langerhan’s cells or dermal dendritic cells to vitamin D leads in one case to the downstream induction of CD25+Foxp3+ regulatory T cell responses, while in the other to Foxp3- type 1 regulatory T cells (Tr1) responses. Similarly, exposure of human immature versus semi-mature dendritic cells to IL-10 leads to distinct regulatory T cell outcomes. Thus, it should be possible to shape our dendritic cell immunotherapy approaches for selective induction of different types of T cell tolerance or to simultaneously induce multiple types of regulatory T cell responses. This may prove an important option as we target diseases in different anatomic compartments or with divergent pathologies in the clinic. Finally, we provide an overview of the use and potential use of these cells clinically, highlighting their potential as tools in an array of settings.